Trial Profile
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered TG101348 in Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jan 2021
Price :
$35
*
At a glance
- Drugs Fedratinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions; First in man
- Sponsors TargeGen
- 08 Dec 2020 Results (n=28) of TED12037 and TED12015 studies assessing long-term safety of fedratinib in pts with MF who received > 24 treatment cycles, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
- 21 Jun 2020 Results (n=28) of open-label, dose-finding and extension studies assessing long-term safety in pts with MF who received >24 cycles of FEDR.presented at the 25th Congress of the European Haematology Association
- 28 Oct 2009 Actual patient number (59) added as reported by ClinicalTrials.gov.